Skip to main content

Grafa News and Videos — Page 1507

Latest

Grafa

AVITA Medical interim results show significant reduction in skin grafting timelines

AVITA Medical (NASDAQ:RCEL) announced on Tuesday, April 14, 2026, positive interim results from its Cohealyx-I clinical study, demonstrating that its dermal matrix significantly accelerates the timeline for skin grafting in complex wounds.

Read more: AVITA Medical interim results show significant reduction in skin grafting timelines
Grafa

Clearmind Medicine hits primary safety endpoint in Phase I/IIa alcohol use disorder trial

Clearmind Medicine (NASDAQ:CMND), a clinical-stage biopharmaceutical company focused on neuro-therapeutics, announced on Tuesday, April 14, 2026, that its lead oral candidate, CMND-100, successfully met the primary safety and tolerability endpoints in an FDA-approved Phase I/IIa dose-escalation trial.

Read more: Clearmind Medicine hits primary safety endpoint in Phase I/IIa alcohol use disorder trial

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift